# A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator in Patients With Amyotrophic Lateral Sclerosis

> **NCT04948645** · PHASE1 · TERMINATED · sponsor: **AbbVie** · enrollment: 31 (actual)

## Conditions studied

- ALS
- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** Fosigotifator
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04948645
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-09-22
- **Primary completion:** 2025-07-15
- **Final completion:** 2025-07-15
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** Company Decision
- **Last updated:** 2025-08-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04948645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04948645, "A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator in Patients With Amyotrophic Lateral Sclerosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04948645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*